Vancoymycin causes red man syndrome, an itchy erythematous eruption involving the face, neck, and upper torso. Atopic dermatitis also manifests itch and erythema, and staphylococcus δ-toxin contributes to this process. The antibiotic and toxin each provoke mast cell degranulation but the mechanism had not been understood. We have determined that these compounds evoke degranulation via interaction with the same receptor, MRGPRX2, on mast cells. A receptor antagonist inhibits this process. Antagonists of this receptor may have therapeutic potential.
MRGPRX2 and staphylococcus δ-toxin
Mast cells have long been implicated in the pathogenesis of atopic dermatitis, an intensely pruritic inflammatory skin disease [1, 2] . As opposed to healthy individuals, > 90% of atopic dermatitis patients are colonized with Staphylococcus aureus in the affected skin areas [3] . Culture supernatants of S. aureus demonstrate potent mast cell degranulation activity and δ-toxin has been identified as the main degranulation inducing factor [4] . Skin colonization with S. aureus, but not a mutant deficient in δ-toxin, promotes interleukin (IL)-4 production and allergic skin disease [4] . These effects are IgE-independent, are diminished in Kit W-sh/W-sh mast cell-deficient mice, and are restored by mast cell reconstitution suggesting a pivotal role for IgE-independent mast cell degranulation in δ-toxin-induced allergic skin disease [4] . Despite these findings, the mechanism by which δ-toxin induces mast cell degranulation remained unknown [4] . Given the role of MRGPRX2 in itch [5, 6] and IgE-independent mast cell degranulation [7] , we evaluated the interaction of δ-toxin with MRGPRX2 using ratiometric Fura-2 imaging in a HEK-293 cell line stably expressing MRGPRX2 (Fig. 1A) . This activation is inhibited by QWF, a MRGPRX2 antagonist [5] (Fig. 1A) . QWF also inhibits δ-toxin-induced degranulation in the human LAD2 mast cell line (Fig. 1B) .
MRGPRX2 and red man syndrome
Human MRGPRX2 and a mouse ortholog, MrgprB2, mediate basic secretagogue-induced mast cell degranulation [7] . Pseudoallergic reactions associated with medications such as fluoroquinolone antibiotics and curare-derived neuromuscular agents are diminished in MrgprB2 − / − mice [7] . Vancomycin is a glycopeptide antibiotic frequently used to treat nosocomial infections and the drug of choice to treat methicillin-resistant staphylococci [9] . Two types of hypersensitivity reactions are associated with vancomycin: one type is IgE-mediated anaphylaxis. The second type is red man syndrome; an IgE-independent mast cell degranulation associated with a pruritic erythematous rash involving the face, neck, and upper torso [9] . Clinical features similar to red man syndrome are observed frequently with ciprofloxacin and atracurium but surprisingly not with teicoplanin, a glycopeptide antibiotic similar to vancomycin [10] . Given the wide clinical implications of glycopeptides and the burden of red man syndrome, we investigated the interaction of vancomycin and teicoplanin with MRGPRX2. Teicoplanin does not activate MRGPRX2 and does not induce mast cell degranulation (Fig. 2) . In contrast, we demonstrate that vancomycin activates human MRGPRX2 and that this activation is inhibited by QWF (Fig. 1A) . QWF significantly decreases vancomycin-induced degranulation in the human LAD2 mast cell line (Fig. 1C) .
Conclusions
Activation of MRGPRX2 on mast cells induces the release of several proinflammatory mediators including histamine, ILs, tumor necrosis factor, and prostaglandin D2 [7, 11] . These findings are consistent with data that has previously implicated MRGPRX2 in itch. The data presented here link MRGPRX2 to 2 specific itchy conditions, red man syndrome associated with vancomycin, and atopic dermatitis, at least within the context of staphylococcus δ-toxin.
Red man syndrome is an acute IgE-independent reaction mediated by mast cells, the symptoms of which are controlled partially by antihistamines. This observation is consistent with the release of histamine from mast cells contributing to red man syndrome although antihistamines do not prevent its occurrence [9] . Atopic dermatitis is a chronic inflammatory skin disease with a complex pathogenesis involving the microbiome, barrier defects, and different inflammatory cells including mast cells. Antihistamines have limited efficacy in the treatment or control of the symptoms of atopic dermatitis [12] . This observation is consistent with the contribution of additional mast cell-derived mediators, for example IL-4, to the pathogenesis of atopic dermatitis.
MRGPRX2 has been detected on mast cells, sensory neurons and, most recently, keratinocytes, where it leads to the release of IL-6 [13, 14] . Substance P, a neuropeptide associated with atopic dermatitis, activates MRGPRX2 and induces scratching in mice via Mrgprs [5] . The data reported here extend the contributions of this receptor to inflammatory conditions associated with itch and erythema with the demonstration that vancomycin and staphylococcus δ-toxin activate mast cells via MRGPRX2. [5, 8] . QWF significantly decreases the mast cell degranulation induced by staphylococcus δ-toxin (P = 0.0022) and vancomycin (P = 0.0003). ** P r 0.01; ***P r 0.001. Antagonists of MRGPRX2 have the potential to relieve the symptoms of or to treat red man syndrome and atopic dermatitis.
